EMEA-002042-PIP02-20-M01
Table of contents
Key facts
| Active substance |
Erdafitinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0190/2022
|
| PIP number |
EMEA-002042-PIP02-20-M01
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except urothelial carcinoma, haematopoietic and lymphoid tissue neoplasms)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Janssen-Cilag International N.V.
E-mail: contact@Janssen-emea.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|